Trusted by Leading Research & Pharma Institutions

Protein High Throughput Screening Services

Accelerate your protein engineering projects with state-of-the-art display technologies. From yeast surface display to phage display and mRNA display, we offer comprehensive screening platforms for antibody discovery, enzyme engineering, and biomarker identification.

Up to 10^14 Library Size

Multiple Platforms

AI-Enhanced Screening

Learn More

Trusted by leading research and pharmaceutical institutions

MIT

Pfizer

Stanford

Roche

Harvard

Novartis

Why Choose Our Screening

Multiple display technology platforms

Deep sequencing validation

AI-assisted hit identification

Rapid screening turnaround

Yeast Display

High-throughput screening for antibodies

Phage Display

Large library screening for binders

mRNA Display

Ultra-large library evolution

Library Size

Up to 10^14

Service Overview

Comprehensive Protein Screening Solutions

From initial library design to final hit validation, our integrated screening platforms accelerate your protein engineering projects with industry-leading efficiency.

Yeast Surface Display

FACS-enabled screening of displayed proteins with quantitative affinity measurement and multi-parameter selection.

Library size: 10^7-10^8 clones
FACS-based screening
Endogenous folding quality control

Phage Display

Proven technology for antibody and peptide discovery with massive library capacity and established workflows.

Library size: up to 10^11 clones
Multiple display formats (M13, T7)
Biopanning optimization

mRNA Display

In vitro selection technology enabling ultra-large library screening for peptide and protein evolution.

Library size: 10^12-10^14 clones
In vitro selection
Non-natural amino acid incorporation

Ribosome Display

Cell-free display technology for in vitro protein evolution with error-prone PCR capabilities.

Cell-free environment
Directed evolution cycles
Multiple selection rounds

Microfluidic Screening

Nanoliter-scale screening technology for single-cell analysis and high-throughput binder identification.

Single-cell resolution
Droplet-based screening
Low sample consumption

AI-Enhanced Analysis

Machine learning algorithms for hit identification, off-rate prediction, and developability assessment.

Sequence-property prediction
Developability scoring
Optimization recommendations

Our Technology

Advanced Display Platforms

We employ a comprehensive suite of display technologies to meet diverse screening requirements.

Core Technology

Yeast Surface Display

Our yeast display platform combines FACS-based screening with eukaryotic post-translational modification and folding quality control. Each yeast cell displays 10^4-10^5 copies of the protein of interest, enabling quantitative affinity measurement by flow cytometry.

Saccharomyces cerevisiae

Well-characterized expression system

FACS Sorting

Multi-parameter selection capability

Quantitative Affinity

Direct measurement by flow cytometry

Eukaryotic PTM

Post-translational modifications

10^4-10^5

Copies per Cell

10^11

Library Diversity

Proven Platform

Phage Display Technology

Our phage display platform supports multiple display formats including M13 filamentous phage and T7 phage. We offer both biopanning and phage ELISA workflows with flexible library construction options.

M13 Filamentous Phage

Phagemid and phage display systems

T7 Phage Display

For large protein display

Target Types

Proteins, peptides, small molecules

mRNA Display

Cell-free display technology enabling in vitro selection from ultra-large libraries with covalent mRNA-protein fusions.

Library size: 10^12-10^14 clones
Non-natural amino acid incorporation
In vitro evolution capability
Covalent linkage stability

Ribosome Display

Another cell-free selection method using stalled ribosome complexes for in vitro protein evolution.

Library size: 10^12-10^13 clones
Genotype-phenotype linkage without transformation
Multiple selection rounds
Complex library handling

Service Specifications

Technical Specifications

Detailed specifications for our protein screening platforms.

Library Specifications

Yeast Display Library 10^7-10^8

Phage Display Library 10^9-10^11

mRNA Display Library 10^12-10^14

Ribosome Display Library 10^12-10^13

Affinity & Screening

Typical KD Range pM to nM

Sub-nanomolar affinities achievable

Screening Rounds 2-5 rounds

Typical enrichment workflow

Validated Hit Rate 0.1-5%

Enriched hit populations from final round

Deep Sequencing Included

Comprehensive hit analysis

Library Types Available

scFv Libraries

Fab Libraries

VHH/Nanobody

Peptide Libraries

Synthetic Libraries

Naive Libraries

Compatible Target Types

Soluble Proteins

Purified protein antigens

Membrane Proteins

GPCRs, ion channels, transporters

Cell Surface Targets

Live cell panning capabilities

Small Molecules

Hapten-carrier conjugates

Service Workflow

Our Screening Process

From library design to hit validation, our integrated workflow ensures efficient and reliable binder discovery.

Consultation

Project assessment and platform recommendation based on your target and requirements.

Target characterization
Library selection
Strategy planning

Library Screening

Systematic panning or sorting to enrich for target-binding variants.

Multiple selection rounds
Counter-selection
Deep sequencing

Hit Validation

Individual clone screening and affinity characterization of selected binders.

ELISA screening
Affinity measurement
Sequence analysis

Delivery

Comprehensive hit report and antibody/reagent delivery.

Full characterization
Sequence info
Technical support

Research Applications

Wide Range of Applications

Our screening platforms support diverse protein engineering applications.

Antibody Discovery

Discovery of monoclonal antibodies, nanobodies, and antibody fragments for therapeutic and diagnostic applications.

Enzyme Engineering

Directed evolution of enzymes for improved activity, stability, or specificity for industrial applications.

Biomarker Discovery

Identification of novel biomarkers and binding partners through peptide and protein display screening.

Diagnostic Development

Development of binding reagents for diagnostic assays including ELISA, lateral flow, and immunoimaging.

Peptide Discovery

Identification of bioactive peptides for therapeutic, diagnostic, or research applications.

Affinity Reagents

Generation of high-affinity binding proteins for research tools, purification, and detection applications.

Customer Testimonials

Trusted by Researchers Worldwide

See what our customers say about their protein screening experience.

"The yeast display screening service helped us identify several high-affinity antibody candidates in just 6 weeks. The FACS-based selection was far more efficient than traditional panning."

Biotech Company

Research Lab

"We needed nanobodies against a challenging membrane protein target. Their phage display library combined with counter-selection yielded excellent results."

Research University

Metabolic Engineering Lab

"The AI-assisted hit analysis was a game-changer. The developability predictions helped us prioritize candidates that would actually work in our assays."

Pharmaceutical Company

Drug Discovery

Scientific Literature

Supported by Peer-Reviewed Research

Our services are built on a foundation of rigorous scientific research and validated methodologies.

Multiplex evolution of antibody fragments utilizing a yeast surface display platform

Oh EJ, Liu R, Liang L, et al. ACS Synth Biol. 2020

CRISPR/Cas9-based trackable editing combined with FACS screening of yeast-displayed libraries for antibody affinity maturation.

View Publication

Growth-decoupled Komagataella phaffii recombinant protein production

Bernat-Camps N, Ebner K, Schusterbauer V, et al. Front Bioeng Biotechnol. 2023

Development of methanol-free expression systems using PDH promoter for Pichia pastoris.

View Publication

Phage display technology as a platform for antibody drug discovery

Nagano K, Tsutsumi Y. Viruses. 2021

Comprehensive review of phage display applications in biomarker discovery and targeted therapy.

View Publication

Large language models generate functional protein sequences

Madani A et al. Nature Biotechnology. 2023

Integration of machine learning with protein display for accelerated engineering.

View Publication

Saccharomyces cerevisiae cell surface display technology

Zhang C, Chen H, et al. Front Bioeng Biotechnol. 2022

Strategies for improvement and applications in enzyme engineering.

View Publication

High-throughput droplet-based microfluidic screening advances

Fu X et al. Frontiers in Chemistry. 2021

Revolutionizing protein and cell screening with microfluidic platforms.

View Publication

FAQ

Frequently Asked Questions

Find answers to common questions about our protein screening services.

Which display platform should I choose for my project?

The choice depends on your target and requirements. Yeast display offers FACS-based quantitative screening with mammalian folding quality control. Phage display provides the largest library sizes and is well-suited for antibody discovery. mRNA display offers ultra-large libraries and allows non-natural amino acid incorporation. Our team will help you select the optimal platform based on your specific project needs.

What library sizes can you work with?

Our platforms support different library sizes: yeast display (10^7-10^9), phage display (10^10-10^12), mRNA display (10^12-10^14), and ribosome display (10^12-10^14). We also offer pre-built libraries with validated diversity for common applications.

Can you screen against difficult targets like membrane proteins?

Yes, we have experience with challenging targets including GPCRs, ion channels, and transporters. For membrane proteins, we offer options including cell-based panning, virus-like particle display, and solublization strategies. Our team will optimize the screening approach based on your target's characteristics.

How long does a typical screening project take?

Typical timelines vary by project complexity: standard antibody discovery (6-12 weeks), enzyme engineering (8-16 weeks), and complex targets (12-20 weeks). The timeline depends on library selection, number of selection rounds, and hit validation requirements. Expedited timelines are available for urgent projects.

What formats are the final hit reagents delivered in?

We deliver characterized hit antibodies as plasmid DNA, purified protein, or both depending on your needs. Each hit includes sequence information, binding characterization data (ELISA, SPR/BLI), and developability assessment. Custom formats and additional characterization can be arranged.

Do you offer affinity maturation services?

Yes, we offer affinity maturation services to improve the binding affinity of initial hits. This includes library generation around CDR regions, additional screening rounds, and affinity measurement by SPR or BLI. Typical maturation campaigns can improve affinity by 10-100 fold.

Can you perform counter-selection to reduce off-target binding?

Absolutely. Counter-selection is a standard part of our screening workflow. We can use irrelevant proteins, related targets, or specific tissues/cell types to deplete cross-reactive binders and improve target specificity.

What developability assessment do you provide?

Our standard hit characterization includes developability assessment such as expression yield, thermal stability (Tm), aggregation propensity, and cross-reactivity screening. We also offer AI-powered developability prediction using machine learning models trained on large antibody property datasets.

Ready to Start Your Project?

Get a customized quote for your Protein High Throughput Screening project. Our experts will respond within 24 hours.

No obligation

24h response

Expert consultation

Request a Quote

Protein High Throughput Screening Services

Why Choose Our Screening

Yeast Display

Phage Display

mRNA Display

Comprehensive Protein Screening Solutions

Yeast Surface Display

Phage Display

mRNA Display

Ribosome Display

Microfluidic Screening

AI-Enhanced Analysis

Ready to Discover Your Next Breakthrough Binder?

Advanced Display Platforms

Yeast Surface Display

Saccharomyces cerevisiae

FACS Sorting

Quantitative Affinity

Eukaryotic PTM

Phage Display Technology

M13 Filamentous Phage

T7 Phage Display

Target Types

mRNA Display

Ribosome Display

Technical Specifications

Library Specifications

Affinity & Screening

Library Types Available

Compatible Target Types

Soluble Proteins

Membrane Proteins

Cell Surface Targets

Small Molecules

Our Screening Process

Consultation

Library Screening

Hit Validation

Delivery

Wide Range of Applications

Antibody Discovery

Enzyme Engineering

Biomarker Discovery

Diagnostic Development

Peptide Discovery

Affinity Reagents

Trusted by Researchers Worldwide

Supported by Peer-Reviewed Research

Multiplex evolution of antibody fragments utilizing a yeast surface display platform

Growth-decoupled Komagataella phaffii recombinant protein production

Phage display technology as a platform for antibody drug discovery

Large language models generate functional protein sequences

Saccharomyces cerevisiae cell surface display technology

High-throughput droplet-based microfluidic screening advances

Frequently Asked Questions

Ready to Start Your Project?

Recommended Services

Related Resources